

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2023/287352 A9

(43) International Publication Date
19 January 2023 (19.01.2023)

WIPO | PCT

(51) International Patent Classification:

C07K 16/08 (2006.01) A61P 31/14 (2006.01)
A61K 39/42 (2006.01) G01N 33/53 (2006.01)

(74) Agent: DOWSING, Bruce John; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O. Box 636, Singapore 910816 (SG).

(21) International Application Number:

PCT/SG2022/050468

(22) International Filing Date:

06 July 2022 (06.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202107784Y 15 July 2021 (15.07.2021) SG

(71) Applicant: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) Inventors: MACARY, Paul Anthony; c/o National University of Singapore, Life Sciences Institute, 21 Lower Kent Ridge Road, Singapore 119077 (SG). JHAJHARIA, Saket; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Microbiology & Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LIM, Seng Gee; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG). CHEN, Qingfeng; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Microbiology & Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LAI, Fritz; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTI-HBV ANTIBODIES AND USES THEREOF




Figure 71

(57) Abstract: The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralizes hepatitis B virus infection, method for producing the same, and uses thereof in treating human HBV infection.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(88) Date of publication of the international search report:

23 February 2023 (23.02.2023)

(48) Date of publication of this corrected version:

23 March 2023 (23.03.2023)

(15) Information about Correction:

see Notice of 23 March 2023 (23.03.2023)